Your Health, We Care
Another Name普吉华、GAVRETO、普雷西替尼、帕拉西替尼、普雷替尼、普拉提尼
IndicationsIt is indicated for adults, adolescents and children aged 12 years and older with metastatic non-small cell lung cancer (NSCLC), as well as patients with advanced or metastatic thyroid cancer.
Reg No.08 L 1007/23
Inspection NO.1978-23
Pralsetinib is a prescription drug approved for marketing by the U.S. Food and Drug Administration (FDA) in September 2020. It is indicated for targeting RET gene fusions (e.g., KIF5B-RET, CCDC6-RET) and activating mutations (e.g., RET V804L/M, M918T), and its use shall be strictly in accordance with the doctor’s instructions.
RET gene fusions (e.g., KIF5B-RET, CCDC6-RET) and activating mutations (e.g., RET V804L/M, M918T).
Pralsetinib can block the uncontrolled proliferation induced by abnormally mutated RET genes in cancer cells.
Administration route and frequency of Pralsetinib: Oral administration, once daily.
The dosage of Mavacamten should be adjusted according to the patient’s actual condition. For specific circumstances, patients should consult a doctor and strictly follow the medical advice.
Recommended Reading: Dosage and Administration of Pralsetinib
Common adverse reactions (≥25%) include musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, fever, and cough.
Reference Article: Adverse Reactions of Pralsetinib
Pediatric Use: Epiphyseal growth plates should be monitored in adolescent patients. If abnormalities occur, consider interrupting or discontinuing GAVRETO.
Lactation: Women are advised not to breastfeed during GAVRETO treatment and within 1 week after the last dose.
Remember to take Pralsetinib capsules as instructed by your doctor.
Do not alter the dosage or discontinue Pralsetinib unless directed by a healthcare provider.
from FDA，2024.03
